Research for
everyday health.

A global research collective initiated in Pakistan, focused on weight, hair, skin and nail health.

Capira Health
About Capira

A focused approach to everyday health.

Capira Pharmaceuticals is a global research collective initiated in Pakistan, working across weight management, hair and scalp health, skin, and nails.

Discover our research, learn about our company, and explore free general wellness assessments through Capira Health.

Drug Discovery

Studying compounds and mechanisms in our four focus areas.

Market Mapping

Understanding the needs of people in Pakistan.

Strategic Partnerships

Open to conversations with researchers and organisations.

Commercialization

Bringing research toward practical use over time.

Research Focus

Core Scientific Domains

Four areas we research and cover in Capira Health.

01

Weight Management

GLP-1 Pathway ResearchMetabolic SyndromeObesity Pharmacotherapy
02

Hair & Scalp Health

Androgenetic AlopeciaJAK InhibitionFollicular Regeneration
03

Nail Health

OnychomycosisNail Matrix DystrophySubungual Delivery
04

Dermatology & Skin

PsoriasisEczemaHyperpigmentation
Research

Published Science

Explore independent research across our four focus areas, followed by the existing Capira-listed papers.

External research

Selected independent studies, reviews and clinical guidelines relevant to our focus areas. These publications are not authored by Capira and do not establish the safety or effectiveness of any Capira product or service.

Background reading, not personal medical advice. Publication years are shown; this is not an exhaustive or continuously updated guideline library. Full-text access may depend on the publisher.

Weight health

Randomized trial2021 · External publication
Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al.

New England Journal of Medicine

The STEP 1 trial compared once-weekly semaglutide with placebo alongside lifestyle intervention in adults with overweight or obesity without diabetes. It reports weight outcomes and adverse events in the studied population.

Hair & scalp

Systematic review2017 · External publication
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis

Adil A, Godwin M.

Journal of the American Academy of Dermatology

A review of randomized trials of nonsurgical treatments for pattern hair loss, including minoxidil, finasteride and low-level light therapy. The authors note substantial differences between the included studies.

Randomized trial2002 · External publication
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men

Olsen EA, Dunlap FE, Funicella T, et al.

Journal of the American Academy of Dermatology

A clinical comparison of two topical minoxidil concentrations and placebo in men with androgenetic alopecia. It provides background on treatment evaluation rather than evidence for a Capira product.

Skin health

Clinical guideline2024 · External publication
Guidelines of care for the management of acne vulgaris

Reynolds RV, Yeung H, Cheng CE, et al.

Journal of the American Academy of Dermatology

American Academy of Dermatology guidance reviewing evidence for acne care, including topical and systemic treatments and responsible antibiotic use. Consult the source record for its linked correction.

Clinical guideline2023 · External publication
Guidelines of care for the management of atopic dermatitis in adults with topical therapies

Sidbury R, Alikhan A, Bercovitch L, et al.

Journal of the American Academy of Dermatology

Evidence-based guidance on topical treatment of adult atopic dermatitis, including moisturizers and prescription therapies. It describes the evidence assessment and limitations behind the recommendations.

Nail health

Randomized trials2013 · External publication
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies

Elewski BE, Rich P, Pollak R, et al.

Journal of the American Academy of Dermatology

Two vehicle-controlled studies evaluated a topical antifungal solution for toenail infection. The paper discusses clinical and mycological outcomes, safety and follow-up limitations.

Capira-listed papers

Existing entries supplied for this site, separate from the external research above. Select a title to read its listed abstract.

Abstract · 1 min read

Abstract

We report the synthesis and pharmacological evaluation of a class of constrained GLP-1 receptor agonist peptide analogues demonstrating superior receptor binding affinity and extended half-life compared to existing approved agents. In preclinical models, CP-W301 produced a statistically significant reduction in adipose tissue accumulation (p < 0.001) and modulated hypothalamic neuropeptide Y signalling, suggesting a dual peripheral-central mechanism of action. These findings establish a compelling basis for clinical investigation in adult obesity.

GLP-1 ReceptorObesityAdipogenesisPeptide AnaloguesMetabolic Syndrome
Journal
Journal of Metabolic Research & Therapeutics
Published
September 2024
Volume
Vol. 18, No. 3, pp. 214–231
DOI
10.1016/j.jmrt.2024.09.003
Request Access
Related
Abstract · 1 min read

Abstract

This study characterises the immunological microenvironment of the perifollicular dermis in patients with androgenetic alopecia, identifying aberrant JAK1/JAK2 signalling as a primary mediator of follicular immune privilege collapse. Our novel topical formulation, CP-H114, selectively inhibits JAK-STAT cascade activation in dermal papilla cells, restoring anagen phase duration by 34% in ex vivo human scalp models. These results position targeted JAK inhibition as a precision therapeutic strategy for pattern hair loss.

AlopeciaJAK-STATDermal PapillaFollicular ImmunologyHair Follicle Cycling
Journal
British Journal of Dermatological Sciences
Published
February 2024
Volume
Vol. 41, No. 1, pp. 88–107
DOI
10.1111/bjds.2024.41.1.088
Request Access
Related
Abstract · 1 min read

Abstract

Nail plate impermeability remains the foremost barrier to effective topical antifungal therapy. We describe the development of CP-N208, a lipid-polymer hybrid nanoparticle system engineered for high transungual drug flux and biofilm-disrupting activity against Trichophyton rubrum. In a 12-week ex vivo penetration study, CP-N208 achieved subungual drug concentrations 8.7-fold above the minimum inhibitory concentration, while demonstrating a favourable safety profile in keratinocyte viability assays. Clinical translation of this platform offers a non-systemic alternative for moderate-to-severe onychomycosis.

OnychomycosisNail DystrophyNanoparticlesAntifungal DeliveryBiofilm Disruption
Journal
International Journal of Pharmaceutical Nanomedicine
Published
November 2023
Volume
Vol. 9, No. 4, pp. 302–319
DOI
10.2147/ijpn.2023.09.04.302
Request Access
Related
Abstract · 1 min read

Abstract

Emerging evidence implicates gut dysbiosis in the attenuation of pharmacological weight loss responses. In this randomised controlled preclinical study, we evaluated the co-administration of CP-W301 with a proprietary precision prebiotic consortium (CP-PBC-7) in diet-induced obese murine models. Combination therapy produced a 41% greater reduction in body mass index equivalents versus CP-W301 monotherapy (p < 0.0001), accompanied by significant upregulation of short-chain fatty acid producers and downregulation of inflammatory Proteobacteria. These findings motivate a microbiome-informed combination strategy for next-generation obesity pharmacotherapy.

Gut MicrobiomeObesityPharmacotherapyDysbiosisCombination Therapy
Journal
Nature Metabolism & Microbiome Reports
Published
June 2023
Volume
Vol. 6, No. 2, pp. 155–174
DOI
10.1038/nmmr.2023.0062
Request Access
Related
Tools

Eight small tools for everyday understanding.

Free, no account. They help you read health language and prepare your own information, not diagnose. Nothing you type is saved in your browser.

About these tools
Capira Health

Capira Health.

Free general wellness assessments for weight, hair, skin and nail health. Not a medical diagnosis.

AI Health CoachEvidence-Informed PlansPersonalised to YouFree to Start
Weight & Metabolic

Personalised nutrition, habit, and lifestyle plans tuned for South Asian diet patterns and insulin resistance.

Habit CoachingNutrition PlanOTC Supplements
Hair & Scalp

Coaching plans for shedding, thinning, and scalp health — built around your hair history, diet, and stress profile.

Scalp RoutineOTC TopicalsNutrition
Skin

Personalised routines for acne, hyperpigmentation, and anti-ageing — formulated for Pakistani skin types and climate.

OTC SkincareSun ProtectionDaily Habits
Nail Health

Plans for brittle nails, ridges, and discolouration — covering diet, supplements, and OTC topical care.

SupplementsOTC TopicalsLifestyle
1 min read
Did You Know?

Adipose tissue is not merely a passive energy store — it is an active endocrine organ secreting over 50 hormones that regulate appetite, inflammation, and insulin sensitivity, making obesity a hormonal condition as much as a caloric one.

Collaboration

Work with Capira.

Select the profile that fits your situation.

01

You're a Biotech

Working in weight, hair, skin or nail health?

+

If you are developing a compound or technology in one of our four focus areas, we are glad to hear about it and discuss whether there is a fit.

You bring
  • Novel compound or IP
  • Pre-clinical or clinical data
  • Therapeutic focus alignment
Capira brings
  • A scientific conversation
  • Focus-area context
  • A clear next step
How it works
1
Get in touch
2
Introductory call
3
Next steps
02

You're a Researcher

Research in our focus areas.

+

If your research relates to weight, hair, skin or nail health, write to us with a short summary. We read every message.

You bring
  • Peer-reviewed findings
  • Novel mechanism or target
  • Expertise in our focus domains
Capira brings
  • A scientific conversation
  • Focus-area context
  • A clear next step
How it works
1
Get in touch
2
Introductory call
3
Next steps
03

You're an Investor

Interested in our work?

+

For investment enquiries, contact us by email for an introduction to Capira's research focus and current work.

You bring
  • Capital deployment mandate
  • Interest in pharma or biotech
  • Appetite for emerging market assets
Capira brings
  • An introductory conversation
  • Research overview
  • A clear next step
How it works
1
Get in touch
2
Introductory call
3
Next steps